Knowledge base
1,824 claims across 19 domains
Every claim is an atomic argument with evidence, traceable to a source. Browse by domain or search semantically.
All 1,824ai alignment 395health 320internet finance 306space development 227entertainment 169grand strategy 141collective intelligence 52mechanisms 34teleological economics 30living agents 30cultural dynamics 29critical systems 24energy 23teleohumanity 18living capital 10robotics 5manufacturing 5unknown 3technology 3
caregiver workforce crisis shows all 50 states experiencing shortages with 43 states reporting facility closures signaling care infrastructure collapse
The paid caregiving workforce crisis has reached universal geographic scope and is now causing structural capacity loss. All 50 US states report home care worker shortages, 92% of nursing homes report significant or severe workforce shortages, and approximately 70% of assisted living facilities face
home based care could capture 265 billion in medicare spending by 2025 through hospital at home remote monitoring and post acute shift
Up to $265 billion in care services—representing 25% of total Medicare cost of care—could shift from facilities to home by 2025, a 3-4x increase from current baseline (~$65 billion). This migration is enabled by three converging forces: proven cost savings from hospital-at-home models (19-30% saving
us long term care financing gap is largest unaddressed structural problem in american healthcare
The United States has no equivalent to Japan's mandatory Long-Term Care Insurance system. Medicare covers acute care but not long-term care. Medicaid covers long-term care only for those who spend down their assets to poverty levels. The gap between these programs is filled by an estimated $870 bill
semaglutide achieves 47 percent one year persistence versus 19 percent for liraglutide showing drug specific adherence variation of 2 5x
Within the GLP-1 receptor agonist class, drug-specific persistence rates vary dramatically: semaglutide maintains 47.1% of non-diabetic obesity patients at one year, while liraglutide retains only 19.2%—a 2.5x difference.
us healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality
The Commonwealth Fund's 2024 Mirror Mirror report compared 10 high-income countries (Australia, Canada, France, Germany, Netherlands, New Zealand, Sweden, Switzerland, United Kingdom, United States) across 70 measures in five performance domains. The US ranked **last overall** while spending more th
glp 1 persistence drops to 15 percent at two years for non diabetic obesity patients undermining chronic use economics
Real-world claims data from 125,474 commercially insured patients initiating GLP-1 receptor agonists for obesity (without type 2 diabetes) reveals a persistence curve that fundamentally challenges the economic model: 46.3% remain on treatment at 180 days, 32.3% at one year, and approximately 15% at
federal budget scoring methodology systematically undervalues preventive interventions because 10 year window excludes long term savings
The CBO vs. ASPE divergence on Medicare GLP-1 coverage reveals a structural bias in how prevention economics are evaluated at the federal policy level. CBO estimates that authorizing Medicare coverage for anti-obesity medications would increase federal spending by $35 billion over 2026-2034. ASPE's
medicare trust fund insolvency accelerated 12 years by tax policy demonstrating fiscal fragility
The Medicare Hospital Insurance Trust Fund's projected exhaustion date collapsed from 2055 (March 2025 CBO estimate) to 2040 (February 2026 revised estimate) — a loss of 12 years of solvency in under one year. The primary driver was Republicans' "Big Beautiful Bill" (signed July 2025), which lowered
lower income patients show higher glp 1 discontinuation rates suggesting affordability not just clinical factors drive persistence
Among the factors associated with GLP-1 discontinuation in commercially insured populations, income level emerges as a significant predictor: lower-income patients show higher discontinuation rates even when controlling for other factors.
glp 1 multi organ protection creates compounding value across kidney cardiovascular and metabolic endpoints
The FLOW trial was designed as a kidney outcomes study but revealed benefits across multiple organ systems in the same patient population. In 3,533 patients with type 2 diabetes and chronic kidney disease:
japan demographic trajectory provides 20 year preview of us long term care challenge
Japan is the most aged country in the world with 28.4% of its population aged 65+ as of 2019, expected to plateau at approximately 40% in 2040-2050. The country currently has 6 million people aged 85+, projected to reach 10 million by 2040. This represents the demographic reality the United States w
family caregiving functions as poverty transmission mechanism forcing debt savings depletion and food insecurity on working age population
Nearly half of family caregivers experience at least one major financial impact from their caregiving responsibilities: taking on debt, stopping retirement savings contributions, or becoming unable to afford food. This represents a systematic transfer of elderly care costs from the formal healthcare
semaglutide reduces kidney disease progression 24 percent and delays dialysis creating largest per patient cost savings
The FLOW trial demonstrated that semaglutide reduces major kidney disease events by 24% (HR 0.76, P=0.0003) in patients with type 2 diabetes and chronic kidney disease over a median 3.4-year follow-up. The trial was stopped early at prespecified interim analysis due to efficacy — the effect was so l
unpaid family caregiving provides 870 billion annually representing 16 percent of total us health economy invisible to policy models
63 million Americans now provide unpaid care to family members, delivering an economic value of $870 billion per year in services that would otherwise require paid healthcare workers. This represents approximately 16% of total US healthcare spending ($5.3 trillion), yet this massive care infrastruct
japan ltci proves mandatory universal long term care insurance is viable at national scale
Japan implemented mandatory public Long-Term Care Insurance (LTCI) on April 1, 2000, creating a universal system that has operated continuously for 25 years. The system is financed through 50% mandatory premiums (all citizens 40+) and 50% taxes (split between national, prefecture, and municipal leve
rpm technology stack enables facility to home care migration through ai middleware that converts continuous data into clinical utility
The $265 billion facility-to-home care migration depends on a specific technology stack: remote patient monitoring sensors (growing 19% CAGR to $138B by 2033) generating continuous physiological data, processed through AI middleware (growing 27.5% CAGR to $8.4B by 2030) that converts raw sensor stre
pace restructures costs from acute to chronic spending without reducing total expenditure challenging prevention saves money narrative
The ASPE/HHS evaluation of PACE (Program of All-Inclusive Care for the Elderly) from 2006-2011 provides the most comprehensive evidence to date that fully integrated capitated care does not reduce total healthcare expenditure but rather redistributes where costs fall across payers and care settings.
pace demonstrates integrated care averts institutionalization through community based delivery not cost reduction
PACE's primary value proposition is not economic but clinical and social: it keeps nursing-home-eligible seniors in the community while maintaining or improving quality of care. The ASPE/HHS evaluation found significantly lower nursing home utilization among PACE enrollees across all measured outcom
AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low risk
By March 2025, 92% of US provider health systems were deploying, implementing, or piloting AI scribes. This technology scaled in 2-3 years — compared to 15 years for EHR adoption. The speed is not an anomaly. It reveals which healthcare workflows AI can actually penetrate and why.
AI native health companies achieve 3 5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output
Healthcare has historically been a labor-intensive industry where revenue scales linearly with headcount. More patients require more clinicians, more billing staff, more care coordinators. This linear scaling constrains margins and creates the workforce bottlenecks that limit access. AI-native healt
consumer willingness to pay out of pocket for AI enhanced care is outpacing reimbursement creating a cash pay adoption pathway that bypasses traditional payer gatekeeping
The conventional assumption in healthcare AI is that adoption requires reimbursement — if CMS doesn't create a CPT code and payers don't cover it, the technology stalls. RadNet's mammography study demolishes this assumption with the largest real-world evidence dataset to date.
FDA is replacing animal testing with AI models and organ on chip as the default preclinical pathway which will compress drug development timelines and reduce the 90 percent clinical failure rate
In April 2025, the FDA announced a strategic roadmap to fundamentally restructure preclinical drug testing. The goal: make animal studies "the exception rather than the norm" within 3-5 years. The endorsed alternatives are AI-based predictive models, organ-on-chip systems, and in silico toxicity pre
CMS is creating AI specific reimbursement codes which will formalize a two speed adoption system where proven AI applications get payment parity while experimental ones remain in cash pay limbo
CMS is building the reimbursement infrastructure for clinical AI through a graduated code system. Category I (permanent) CPT codes now exist for AI-assisted diabetic retinopathy autonomous screening, with coronary plaque assessment AI added in 2026. Multiple category III (temporary/experimental) cod
Devoted is the fastest growing MA plan at 121 percent growth because purpose built technology outperforms acquisition based vertical integration during CMS tightening
Devoted Health's Medicare Advantage membership grew 121 percent, making it the fastest-growing MA plan in the country during a period when the largest incumbents are contracting. UnitedHealth expects to lose 1 million MA members in 2026 from repricing driven by margin pressure. Humana faces an estim
the healthcare attractor state is a prevention first system where aligned payment continuous monitoring and AI augmented care delivery create a flywheel that profits from health rather than sickness
Healthcare is civilization's largest coordination failure. The US spends $5.3 trillion annually — 18% of GDP, $15,000 per person, 2.5x the OECD average — and gets worse outcomes than every comparable nation. Life expectancy is 2.7 years below the OECD average. Maternal mortality is several times hig
Page 11 of 13